Tobacco Use Disorder: Clinical Trials

77 trials for Tobacco Use Disorder, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

60 completed, 6 terminated, 5 unknown, 4 recruiting. 77 Phase 3, 25 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 377Completed 60, Terminated 6, Unknown 5, Recruiting 4, Active not recruiting 2
Phase 225Completed 17, Unknown 4, Terminated 3, Recruiting 1

Follow Tobacco Use Disorder: new trials by email Literature Review of Tobacco Use Disorder trials Research Report on Tobacco Use Disorder

Trials (filtered) newest first · largest first

All 77 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study Of Vagal Nerve Stimulation In Conjunction With NRT For Smoking Cessation
Non-invasive vagus nerve stimulator plus nicotine replacement patches, nicotine replacement patches - Smoking Cessation
Phase 2 / Phase 3RecruitingMayo Clinic1502026-06-042026-09-25
Semaglutide for Smoking Cessation in Patients With Diabetes
Semaglutide, Nicotine replacement - Diabetes Mellitus, Type 2, Nicotine Addiction
Phase 3RecruitingOttawa Heart Institute Research Corporation1002026-02-132026-09-08
Cannabis-Tobacco Co-Use Treatment Study
Varenicline, Counseling, Psychosocial modules - Tobacco Use Disorder, Tobacco Use Cessation
Phase 3RecruitingMedical University of South Carolina2002025-05-062026-04-03
Community-based Smoking Cessation Treatment for Adults With High Stress Sensitivity.
Aerobic Exercise, Counseling, Nicotine patch - Nicotine Dependence
Phase 3RecruitingJasper A. Smits3602023-12-272026-05-15
Efficacy and Safety of Combination EMB-001 as a Potential Smoking Cessation Treatment
EMB-01 - Smoking Cessation, Tobacco Use Disorder
Phase 2 / Phase 3UnknownRose Research Center, LLC252021-05-192021-05-28
Optimizing Tobacco Use Treatment for PLWHA
Varenicline, Nicotine patch, Standard treatment - HIV/AIDS, Nicotine Dependence
Phase 3Active not recruitingAbramson Cancer Center at Penn Medicine3402020-02-172026-09-04
Early Withdrawal Exposure and Negative Affect Withdrawal (NAW) Regulation Training for Smoking Cessation
cognitive-behavioral withdrawal regulation strategies, relaxation strategies, early withdrawal exposure - Tobacco Dependence
Phase 3Active not recruitingUniversity of Alabama at Birmingham4002019-08-012026-10-30
Comparing NicoBloc to Nicotine Lozenges
NicoBloc, Nicotine Lozenge - Smoking Cessation, Nicotine Dependence
Phase 2 / Phase 3CompletedUniversity of Alabama at Birmingham452019-03-212025-04-08
Impact of Very Low Nicotine Content Cigarettes in a Complex Marketplace
Very Low Nicotine Content Cigarettes, Normal Nicotine Content Cigarettes - Tobacco Smoking, Nicotine Dependence
Phase 3CompletedUniversity of Minnesota7992018-06-012024-08-20
Optimizing Tobacco Dependence Treatment in the Emergency Department
Brief Negotiated Interview (BNI), Nicotine replacement therapy (NRT), CT Smokers Quitline (QL) - Tobacco Use Disorder
Phase 3CompletedYale University10562017-02-132020-12-04
Switching to Very Low Nicotine Content Cigarettes vs Reducing Cigarettes Per Day
Very low nicotine content (VLNC) cigarettes and nicotine replacement therapy (NRT), Reduce cigarettes per day (CPD) with nicotine replacement therapy (NRT) - Tobacco Use Disorder
Phase 2 / Phase 3CompletedUniversity of Vermont742017-02-082022-10-04
Examination of Sleep, Smoking Cessation, and Cardiovascular Health
Sleep Advancement Counseling, General Health Information - Nicotine Dependence
Phase 3CompletedUniversity of Delaware302016-11-012019-08-30
Efficacy and Neural Correlates of Personalized Treatment With Transdermal Nicotine Replacement
Nicotine patch, Nicotine mouthspray - Tobacco Use Disorder, Nicotine Dependence
Phase 2 / Phase 3TerminatedCentre for Addiction and Mental Health182015-07-012018-07-19
Study to Determine the Efficacy and Safety of a Novel Nicotine Replacement Therapy
Nicotine Spray, Placebo - Tobacco Dependence
Phase 3CompletedMcNeil Consumer Healthcare Division of McNEIL-PPC, Inc.11982015-01-312019-01-08
Smoking Cessation Versus Long-term Nicotine Replacement Among High-risk Smokers
Standard Smoking Cessation, Extended Nicotine Replacement Therapy, Nicotine replacement therapy - Smoking, Pulmonary Disease, Chronic Obstructive
Phase 3CompletedUniversity of Kansas Medical Center3982014-05-012017-10-06
Dissemination of a Tailored Tobacco Quitline for Rural Veteran Smokers
Nicotine replacement therapy - Transdermal nicotine patch, Nicotine replacement therapy - Nicotine gum, Nicotine replacement therapy - Nicotine lozenge - Nicotine Dependence, Tobacco Use
Phase 3UnknownMark Vander Weg4112013-07-012017-07-11
Providing Free Nicotine Patches to Quitline Smokers
Telephone counseling, Voucher, Nicotine patches - Smoking Cessation
Phase 3CompletedUniversity of California, San Diego37062013-04-012020-02-19
Extended Varenicline Treatment for Smoking Among Cancer Patients
Varenicline, Placebo, Smoking Cessation Counseling - Nicotine Dependence
Phase 3CompletedUniversity of Pennsylvania2072013-01-012019-07-30
Studying the Effects of Administration of Polyunsaturated Fatty Acids (PUFAS) of Omega-3 Series in Nicotine Dependence
Omega 3, Placebo - Tobacco Dependence, Nicotine Dependence
Phase 3CompletedFederal University of São Paulo582013-01-012020-10-14
Varenicline for Nicotine Dependence Among Those With HIV/AIDS
Varenicline, Placebo, Smoking Cessation Counseling - Nicotine Dependence
Phase 3CompletedUniversity of Pennsylvania1792012-10-012019-09-18

Showing 20 of 77. Sign in to see all of them.

Narrower conditions

Smoking Cessation (33)  ·  Smoking (22)  ·  Tobacco Use Cessation (11)  ·  Tobacco Use (6)  ·  Cigarette Smoking (5)  ·  Alcoholism (3)  ·  Depression (3)  ·  Acquired Immunodeficiency Syndrome (2)  ·  Behavior, Addictive (2)  ·  Cardiovascular Diseases (2)  ·  HIV Infections (2)  ·  Alcohol Drinking (1)  ·  Asthma (1)  ·  Body Weight (1)

Broader conditions

Chemically-Induced Disorders (77)  ·  Mental Disorders (77)  ·  Substance-Related Disorders (77)  ·  Behavior (55)  ·  Health Behavior (39)  ·  Smoking (6)  ·  Tobacco Use (6)  ·  Immune System Diseases (5)  ·  Tobacco Smoking (5)  ·  Blood-Borne Infections (4)  ·  Communicable Diseases (4)  ·  Genital Diseases (4)  ·  Immunologic Deficiency Syndromes (4)  ·  Infections (4)  ·  Lentivirus Infections (4)

Interventions

Tobacco Use Cessation Devices (24)  ·  Varenicline (23)  ·  Bupropion (11)  ·  Nicotine (11)  ·  Nicotine Replacement Therapy (5)  ·  Counseling (4)  ·  Nicotine Chewing Gum (4)  ·  Sugars (4)  ·  Fluoxetine (2)  ·  Naltrexone (2)  ·  Topiramate (2)  ·  Behavior Therapy (1)  ·  Crisis Intervention (1)  ·  Decision Support Techniques (1)  ·  Docosahexaenoic Acids (1)

Sponsors

Mayo Clinic (11)  ·  National Institute on Drug Abuse (NIDA) (7)  ·  University of California, San Francisco (6)  ·  Duke University (3)  ·  Queen Mary University of London (3)  ·  University of California, San Diego (3)  ·  University of Minnesota (3)  ·  University of Pennsylvania (3)  ·  Butler Hospital (2)  ·  M.D. Anderson Cancer Center (2)  ·  McNeil Consumer Healthcare Division of McNEIL-PPC, Inc. (2)  ·  Medical University of South Carolina (2)  ·  UConn Health (2)  ·  US Department of Veterans Affairs (2)  ·  University Hospital, Gentofte, Copenhagen (2)

Countries

United States (66)  ·  Canada (3)  ·  United Kingdom (3)  ·  Denmark (2)  ·  Australia (1)  ·  Brazil (1)  ·  France (1)

Top investigators

Jon O Ebbert, MD (3)  ·  Shu-Hong Zhu, Ph.D. (3)  ·  Eric T. Moolchan, M.D. (2)  ·  Gary Humfleet, Ph.D. (2)  ·  Jed E Rose, Ph.D. (2)  ·  Jon O. Ebbert, M.D. (2)  ·  Marc E Mooney, Ph.D. (2)  ·  Paul Cinciripini, PhD (2)  ·  Robert A Schnoll, PhD (2)  ·  Al-Rehan A A Dhanji, MB BS BSc MRCP (1)  ·  Al-Rehan A A Dhanji, MB BS BSc MRCS (1)  ·  Al-Rehan Abdul Aziz Dhanji, MB.BS., BSc.,MRCS. (1)  ·  Amit Sood, M.D. (1)  ·  Andrew Myers, MD (1)  ·  Bankole A Johnson, MD (1)

Results publications

PMID 37142273, PMID 37230961, PMID 34611902, PMID 39101506, PMID 39868569, PMID 30946162, PMID 17295567, PMID 17624979, PMID 17984409, PMID 18447101, PMID 18796184, PMID 19023824, PMID 19392908, PMID 19778993, PMID 20798023, PMID 20947286, PMID 21518946, PMID 22007015, PMID 22097928, PMID 22352784, PMID 22713093, PMID 22993168, PMID 23024246, PMID 23177384, PMID 23454876, PMID 23460656, PMID 23536105, PMID 23718718, PMID 23873976, PMID 24057996, PMID 24075226, PMID 24128381, PMID 24329972, PMID 24345356, PMID 24934962, PMID 25012994, PMID 25187423, PMID 25545858, PMID 25588294, PMID 25732567, PMID 26711164, PMID 27081187, PMID 27213949, PMID 28549161, PMID 29287665, PMID 29324248, PMID 29329763, PMID 29895280, PMID 29986268, PMID 30452732

NIH funding

P50DA009253 (3), K01DA019446 (2), P50DA027840 (2), R01DA002538 (2), 2005 (1), 2008 (1), K24AA013736 (1), M01RR006192 (1), R01AA019720 (1), R01CA118035 (1), R01CA121165 (1), R01CA133068 (1), R01CA201873 (1), R01CA243914 (1), R01CA273221 (1)